BIOX
Overvalued by 328.8% based on the discounted cash flow analysis.
Market cap | $284.71 Million |
---|---|
Enterprise Value | $549.91 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $0.05 |
Beta | 0.44 |
Outstanding Shares | 62,822,158 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 111.01 |
---|---|
PEG | -1424.86 |
Price to Sales | 0.78 |
Price to Book Ratio | 0.94 |
Enterprise Value to Revenue | 1.35 |
Enterprise Value to EBIT | 16.38 |
Enterprise Value to Net Income | 219 |
Total Debt to Enterprise | 0.54 |
Debt to Equity | 0.95 |
No data
No data